Premium
Quantitative assessment of small intraosseous prostate cancer burden in SCID mice using fluorescence imaging
Author(s) -
Yamamoto Hamilto,
Bonfil R. Daniel,
Wiesner Christoph,
Nabha Sanaa,
Dong Zhong,
Meng Hong,
Saliganan Allen,
Sabbota Aaron,
Chinni Sreenivasa R.,
Cher Michael L.
Publication year - 2006
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20506
Subject(s) - ex vivo , prostate cancer , in vivo , medicine , fluorescence lifetime imaging microscopy , pathology , histology , prostate , bone imaging , preclinical imaging , cancer , fluorescence , nuclear medicine , biology , physics , microbiology and biotechnology , quantum mechanics
BACKGROUND Experimental bone metastases are typically analyzed when the skeletal tumor burden is large enough to be detected by imaging or histology. By this time, the bone microenvironment is usually destroyed, preventing useful analysis of tumor–bone interactions. METHODS Small intraosseous tumors generated by intratibial injection of C4‐2B prostate cancer cells transfected with green fluorescent protein (GFP) were assessed using in vivo and ex vivo fluorescence imaging, radiography, histology, and fluorometric analysis of bone lysates. RESULTS Ex vivo fluorescence imaging and fluorometric analysis were capable of detecting tiny bone tumors as early as 10 days after injection. Ex vivo fluorescence imaging allowed simple quantification of small skeletal tumor burden and was useful in measuring the effect of systemic therapy. CONCLUSIONS Ex vivo fluorescence imaging is a sensitive and easy method to quantify small skeletal tumor burden. This technique allows investigation of tumor–bone interactions while the bone microanatomy is still intact. Prostate 67:107–114, 2007. © 2006 Wiley‐Liss, Inc.